Moderna to make milestone payments to NIH for COVID vaccine
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
Vekluryﾮ (Remdesivir) reduced risk of mortality in hospitalized COVID-19 patients across all variants in real world study
On Feb. 21, 2023, Gilead Sciences announced positive data from three retrospective real-world studies which demonstrated that initiation…
Higher-Dose and longer duration of Ivermectin not effective with COVID-19
On Feb. 20, 2023, results from a randomized clinical trial of Ivermectin in a higher-hose and longer duration…
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
Lancet study published on natural immunity protection by COVID variant
On Feb. 16, 2023, it was reported in the Lancet that protection from past infection against re-infection from…
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
U.S. Government and Novavax extend partnership for 1.5 million additional doses of Novavax’ COVID-19 vaccine
On Feb. 13, 2023, Novavax announced a modification to its existing agreement with the U.S. Department of Health…
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Vaccine
BD received FDA EUA for COVID-19, influenza A/B, RSV combination test
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
Bivalent boosters provided better protection against severe COVID-19
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
U.S. household spread of flu more than doubled during the 2021-2022 season compared to pre-COVID-19 pandemic levels
On Jan. 26, 2023, Centers for Disease Control and Prevention (CDC) reported that U.S. household spread of flu…
Roche launched COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
On Jan. 25, 2023, Roche and its subsidiary TIB Molbiol announced they had developed a COVID-19 PCR test…
OHSU researchers found immune response to COVID-19 strengthens over time
On Jan. 25, 2023, researchers at Oregon Health & Science University (OHSU) reported that Immunity from COVID-19 appears…
Novavax Nuvaxovid COVID-19 vaccine approved in South Korea as an adult booster
On Jan. 18, 2023, Novavax announced that partner SK bioscience had received expanded manufacturing and marketing approval from…
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
Single booster dose with updated bivalent COVID-19 vaccine provides broad protection against COVID-19 including Omicron variant
On Jan. 11, 2023, the U.S. Food and Drug Administration reported that a single booster dose with an…
Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
NIH launched Home Test to Treat, a pilot COVID-19 telehealth program
On Jan. 5, 2023, the National Institutes of Health, in collaboration with the Administration for Strategic Preparedness and…
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
FDA approved Roche’s Actemra for treatment of COVID-19 in hospitalised adults
On Dec. 21, 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Actemraﾮ (tocilizumab)…
U.S. Department of Health and Human Services increased access to Tamiflu through the Strategic National Stockpile
On Dec. 21, 2022, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic…
Study revealed that duration of exposure to COVID-19 plays major role in risk of catching the virus
On Dec. 20, 2022, the University of Oxford announced study results using data from 7 million people notified…
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
Swiss and French health authorities expanded recommendations for use of Nuvaxovid COVID-19 vaccine as booster
On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite…
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
COVID-19 vaccine from Washington University in St. Louis approved for use as booster in India
On Dec. 9, 2022, Washington University in St. Louis announced that it’s nasal COVID-19 vaccine technology had been…
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…